Penn Medicine Provider
Medical Oncology
Lova L. Sun, MD, MSCE
4.9
(171)
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Perelman 2nd Floor West

About me

  • Assistant Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania

Education and training

  • Medical School: University of Pennsylvania School of Medicine
  • Residency: Massachusetts General Hospital
  • Fellowship: Hospital of the University of Pennsylvania

What my patients think about me

Average Rating
4.9

171 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

June 2025
5.0
5.0
professional and courteous.
May 2025
5.0
5.0
she is one excellent doctor!
May 2025
5.0
5.0
i feel dr sun is giving me great care, answers all my questions and provides good solutions.
May 2025
5.0
5.0
she makes you feel comfortable and she explains everything so that you can understand

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Sun is a Penn Medicine physician.

Qualifications and experience

My research

Melina E Marmarelis 1 2, Dylan G Scholes 1 3, Tara L McWilliams 4 5, Wei-Ting Hwang 2 4 5, John Kosteva 1, Michael R Costello 1, Lova Sun 1 2, Aditi P Singh 1 2, Kelsey S Lau-Min 6, Abigail Doucette 2 3, Peter E Gabriel 2 3 7, Anthony O Martella 3, Megan A Roy 1 2, Jeffrey C Thompson 2 8, Roger B Cohen 1 2, David W Dougherty 1 2, Lawrence N Shulman 1 2 3, Corey J Langer 1 2, Justin E Bekelman 2 3 7, Erica L Carpenter 1 2, Charu Aggarwal 1 2 3 Electronic Medical Record-Based Nudge Intervention to Increase Comprehensive Molecular Genotyping in Patients With Metastatic Non-Small Cell Lung Cancer: Results From a Prospective Clinical Trial , JCO Oncol Pract, 20(12): 2024


Jacob B Reibel 1, Lova L Sun 1, Ravi B Parikh 1 2, Nadim Mahmud 3 4, Lainie P Martin 1, Rebecca A Hubbard 5, Ronac Mamtani 1 Real-world impact of the platinum chemotherapy shortage on US patients with advanced cancer , J Natl Cancer Inst: 2024


Connor B Grady 1, Wei-Ting Hwang 1, Joshua E Reuss 2, Wade Iams 3, Amanda Cass 3, Geoffrey Liu 4, Devalben Patel 4, Stephen V Liu 2, Gabriela Liliana Bravo Montenegro 2, Tejas Patil 5, Jorge J Nieva 6, Amanda Herrmann 6, Kristen A Marrone 7, Vincent K Lam 7, William Schwartzman 8, Jonathan Dowell 8, Liza C Villaruz 9, Kelsey Leigh Miller 10, Jared Weiss 10, Fangdi Sun 11, Vamsidhar Velcheti 12, D Ross Camidge 5, Charu Aggarwal 13, Lova Sun 13, Melina E Marmarelis 13 Determining Line of Therapy from Real-World Data in Non-Small Cell Lung Cancer , Pharmacoepidemiol Drug Saf, 33(12): 2024


Glenn J Hanna 1, Jamie Jabalee 2, John N Lukens 3, Lova Sun 3, Eleni M Rettig 4, Rocco Ferrandino 2nd 5, Marshall R Posner 5, Krzysztof J Misiukiewicz 5, David M Routman 6, Kathryn M Van Abel 6, Catherine Del Vecchio Fitz 2, Scott A Roof 5 Circulating tumor tissue modified viral (TTMV)-HPV DNA in Recurrent, metastatic HPV-driven oropharyngeal cancer , Oral Oncol, 158: 2024


Elghawy O, Barsouk A, Xu J, Chen S, Cohen RB, Sun L. Real word outcomes of cabozantinib therapy in poorly differentiated thyroid carcinoma , Eur Thyroid J: 2024


Omar Elghawy 1, Adam Barsouk 1, Jessica Xu 1, Simon Chen 2, Roger B Cohen 1, Lova Sun 1 Real word outcomes of cabozantinib therapy in poorly differentiated thyroid carcinoma , Eur Thyroid J, 13(6): 2024


Lova Sun 1, Roger B Cohen 2, A Dimitrios Colevas 3 Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC) , Oral Oncol, 158: 2024


Aman M Patel 1, Afash Haleem 1, Lucy Revercomb 1, Jason A Brant 2 3, Karthik Rajasekaran 2, Lova L Sun 4, Robert M Brody 2 3, Ryan M Carey 2 3 Primary site surgical resection in cM1 oral cavity squamous cell carcinoma , Laryngoscope Investig Otolaryngol, 9(5): 2024


Elghawy O, Barsouk A, Heidlauf A, Chen S, Cohen RB, Sun L. Single-Institution Experience of Larotrectinib Therapy for Patients With NTRK Fusion-Positive Thyroid Carcinoma , J Endocr Soc, 8: 2024,bvae158


Adam Barsouk 1, Omar Elghawy 2, Alec Heidlauf 3, Connie Yu 3, Lucy Wang 3, David Yang 3, Martin Kurian 3, Keshav Goel 3, Lynn Rushkin 3, Anna Anran Huang 3, Lauren Reed-Guy 2, Benjamin Bleiberg 2, Lova Sun 2, Aditi Singh 2, Roger B Cohen 2, Charu Aggarwal 2, Melina Marmarelis 2, Corey Langer 2 Real-world outcomes of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) treated with osimertinib (osi) vs. Afatinib or erlotinib , Lung Cancer, 195: 2024